The U.S. Food and Drug Administration (FDA) has approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab), for the treatment of multiple chronic inflammatory diseases, including psoriasis and psoriatic arthritis.
Cyltezo is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Cyltezo is also indicated, alone or in combination with traditional disease-modifying antirheumatic drugs, or DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
The biosimilar, which is manufactured by Boehringer Ingelheim Pharmaceuticals, is administered with a pre-filled syringe. The company is also seeking approval for an auto-injector.
Cyltezo is not commercially available at this time due to pending litigation.
Read more about biosimilars.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.